Stockreport

Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis

Organogenesis Holdings Inc. - Class A  (ORGO) 
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm Check Earnings Report
PDF CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufa [Read more]